{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:46:39Z","timestamp":1790509599437,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100010414","name":"Health Research Board","doi-asserted-by":"publisher","award":["HRA_POR\/2011\/23"],"award-info":[{"award-number":["HRA_POR\/2011\/23"]}],"id":[{"id":"10.13039\/100010414","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010414","name":"Health Research Board","doi-asserted-by":"publisher","award":["HRA_POR\/2012\/32"],"award-info":[{"award-number":["HRA_POR\/2012\/32"]}],"id":[{"id":"10.13039\/100010414","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011102","name":"Seventh Framework Programme","doi-asserted-by":"publisher","award":["278948"],"award-info":[{"award-number":["278948"]}],"id":[{"id":"10.13039\/100011102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011102","name":"Seventh Framework Programme","doi-asserted-by":"publisher","award":["FP7\/2007-2013"],"award-info":[{"award-number":["FP7\/2007-2013"]}],"id":[{"id":"10.13039\/100011102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001602","name":"Science Foundation Ireland","doi-asserted-by":"publisher","award":["INFANT SFI\/12\/RC\/2272"],"award-info":[{"award-number":["INFANT SFI\/12\/RC\/2272"]}],"id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001602","name":"Science Foundation Ireland","doi-asserted-by":"publisher","award":["SFI\/12\/RC\/2273"],"award-info":[{"award-number":["SFI\/12\/RC\/2273"]}],"id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004963","name":"Seventh Framework Programme","doi-asserted-by":"publisher","award":["241479"],"award-info":[{"award-number":["241479"]}],"id":[{"id":"10.13039\/501100004963","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.ejphar.2015.12.001","type":"journal-article","created":{"date-parts":[[2015,12,12]],"date-time":"2015-12-12T10:28:45Z","timestamp":1449916125000},"page":"117-125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["In vitro bidirectional permeability studies identify pharmacokinetic limitations of NKCC1 inhibitor bumetanide"],"prefix":"10.1016","volume":"770","author":[{"given":"Maria D.","family":"Donovan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harri\u00ebt","family":"Schellekens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine B.","family":"Boylan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Cryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan T.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2015.12.001_bib1","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.addr.2011.11.008","article-title":"Cerebral expression of drug transporters in epilepsy","volume":"64","author":"Aronica","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejphar.2015.12.001_bib2","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1002\/jps.23266","article-title":"Development of a physiologically based pharmacokinetic model for the rat central nervous system and determination of an in vitro\u2013in vivo scaling methodology for the blood\u2013brain barrier permeability of two transporter substrates, morphine and oxycodone","volume":"101","author":"Ball","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejphar.2015.12.001_bib3","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1528-1167.2006.00453.x","article-title":"Lack of interactions between breast cancer resistance protein (bcrp\/abcg2) and selected antiepileptic agents","volume":"47","author":"Cerveny","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejphar.2015.12.001_bib4","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1517\/17425255.2013.741589","article-title":"Species differences in drug transporters and implications for translating preclinical findings to humans","volume":"9","author":"Chu","year":"2013","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"3","key":"10.1016\/j.ejphar.2015.12.001_bib5","doi-asserted-by":"crossref","first-page":"e57148","DOI":"10.1371\/journal.pone.0057148","article-title":"Bumetanide enhances phenobarbital efficacy in a rat model of hypoxic neonatal seizures","volume":"8","author":"Cleary","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2015.12.001_bib6","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1523-1755.2004.00354.x","article-title":"Characterization of uremic toxin transport by organic anion transporters in the kidney","volume":"65","author":"Deguchi","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2015.12.001_bib7","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/jphp.12341","article-title":"The effect of organic anion transporter 3 inhibitor probenecid on bumetanide levels in the brain: an integrated in vivo microdialysis study in the rat","volume":"67","author":"Donovan","year":"2015","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejphar.2015.12.001_bib8","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/nm1301","article-title":"NKCC1 transporter facilitates seizures in the developing brain","volume":"11","author":"Dzhala","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2015.12.001_bib9","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/ana.21229","article-title":"Bumetanide enhances phenobarbital efficacy in a neonatal seizure model","volume":"63","author":"Dzhala","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejphar.2015.12.001_bib10","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.tiv.2004.06.011","article-title":"In vitro models for the blood\u2013brain barrier","volume":"19","author":"Garberg","year":"2005","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.ejphar.2015.12.001_bib11","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1021\/mp300334r","article-title":"P-glycoprotein, breast cancer resistance protein, Organic Anion Transporter 3, and Transporting Peptide 1a4 during blood\u2013brain barrier maturation: involvement of Wnt\/beta-catenin and endothelin-1 signaling","volume":"10","author":"Harati","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejphar.2015.12.001_bib12","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1124\/jpet.103.059139","article-title":"Interactions of human organic anion transporters with diuretics","volume":"308","author":"Hasannejad","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2015.12.001_bib13","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1111\/jphp.12122","article-title":"Modulation of P-glycoprotein in rat brain microvessel endothelial cells under oxygen glucose deprivation","volume":"65","author":"Ji","year":"2013","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejphar.2015.12.001_bib14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1124\/jpet.103.049197","article-title":"Contribution of organic anion transporter 3 (Slc22a8) to the elimination of p-aminohippuric acid and benzylpenicillin across the blood\u2013brain barrier","volume":"306","author":"Kikuchi","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2015.12.001_bib15","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/bdd.267","article-title":"Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects","volume":"22","author":"Kim","year":"2001","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejphar.2015.12.001_bib16","doi-asserted-by":"crossref","first-page":"13675","DOI":"10.1074\/jbc.274.19.13675","article-title":"Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain","volume":"274","author":"Kusuhara","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2015.12.001_bib17","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/chromsci\/39.10.425","article-title":"Quantitative determination of the loop diuretic bumetanide in urine and pharmaceuticals by high-performance liquid chromatography with amperometric detection","volume":"39","author":"Legorburu","year":"2001","journal-title":"J. Chromatogr. Sci."},{"key":"10.1016\/j.ejphar.2015.12.001_bib18","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1038\/tp.2012.124","article-title":"A randomised controlled trial of bumetanide in the treatment of autism in children","volume":"2","author":"Lemonnier","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.ejphar.2015.12.001_bib19","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jchromb.2011.02.018","article-title":"Sensitive isotope dilution liquid chromatography\/tandem mass spectrometry method for quantitative analysis of bumetanide in serum and brain tissue","volume":"879","author":"Li","year":"2011","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.ejphar.2015.12.001_bib20","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/pr.2012.7","article-title":"Bumetanide augments the neuroprotective efficacy of phenobarbital plus hypothermia in a neonatal hypoxia-ischemia model","volume":"71","author":"Liu","year":"2012","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ejphar.2015.12.001_bib21","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.mam.2012.10.012","article-title":"Transporter biology in drug approval: regulatory aspects","volume":"34","author":"Maeda","year":"2013","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.ejphar.2015.12.001_bib22","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejps.2014.04.004","article-title":"Inhibitory effects of p-aminohippurate and probenecid on the renal clearance of adefovir and benzylpenicillin as probe drugs for organic anion transporter (OAT) 1 and OAT3 in humans","volume":"59","author":"Maeda","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejphar.2015.12.001_bib23","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1124\/jpet.102.039255","article-title":"Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs","volume":"303","author":"Mahar Doan","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2015.12.001_bib24","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1021\/mp400294x","article-title":"Innovative in vitro method to predict rate and extent of drug delivery to the brain across the blood\u2013brain barrier","volume":"10","author":"Mangas-Sanjuan","year":"2013","journal-title":"Mol. Pharm."},{"issue":"6","key":"10.1016\/j.ejphar.2015.12.001_bib25","doi-asserted-by":"crossref","first-page":"927","DOI":"10.33549\/physiolres.931897","article-title":"Age- and dose-specific anticonvulsant action of bumetanide in immature rats","volume":"58","author":"Mares","year":"2009","journal-title":"Physiol. Res."},{"key":"10.1016\/j.ejphar.2015.12.001_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/nm.3987","article-title":"Treatment during a vulnerable developmental period rescues a genetic epilepsy","author":"Marguet","year":"2015","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.ejphar.2015.12.001_bib27","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1111\/j.1528-1167.2009.02048.x","article-title":"Bumetanide inhibits rapid kindling in neonatal rats","volume":"50","author":"Mazarati","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejphar.2015.12.001_bib28","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1124\/dmd.107.019828","article-title":"Role of organic anion transporters in the pharmacokinetics of zonampanel, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, in rats","volume":"36","author":"Minematsu","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejphar.2015.12.001_bib29","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1124\/dmd.110.036863","article-title":"Organic anion transporter 3 mediates the efflux transport of an amphipathic organic anion, dehydroepiandrosterone sulfate, across the blood\u2013brain barrier in mice","volume":"39","author":"Miyajima","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejphar.2015.12.001_bib30","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1124\/jpet.107.121491","article-title":"Species difference in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human kidney slices","volume":"322","author":"Nozaki","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2015.12.001_bib31","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1038\/npp.2013.120","article-title":"P-glycoprotein inhibition increases the brain distribution and antidepressant-like activity of escitalopram in rodents","volume":"38","author":"O'Brien","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2015.12.001_bib32","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1111\/j.1471-4159.2007.04901.x","article-title":"Brain-to-blood elimination of 24S-hydroxycholesterol from rat brain is mediated by organic anion transporting polypeptide 2 (oatp2) at the blood\u2013brain barrier","volume":"103","author":"Ohtsuki","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2015.12.001_bib33","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0022-3565(24)29270-3","article-title":"Rational use of in vitro P-glycoprotein assays in drug discovery","volume":"299","author":"Polli","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2015.12.001_bib34","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.addr.2011.12.007","article-title":"Role of CNS efflux drug transporters in antiepileptic drug delivery: overcoming CNS efflux drug transport","volume":"64","author":"Potschka","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5","key":"10.1016\/j.ejphar.2015.12.001_bib35","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S1474-4422(14)70303-5","article-title":"Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1\/2 trial","volume":"14","author":"Pressler","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2015.12.001_bib36","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/epi.12620","article-title":"Pharmacotherapeutic targeting of cation-chloride cotransporters in neonatal seizures","volume":"55","author":"Puskarjov","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejphar.2015.12.001_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12012-011-9145-8","article-title":"The history and future of probenecid","volume":"12","author":"Robbins","year":"2012","journal-title":"Cardiovasc. Toxicol."},{"key":"10.1016\/j.ejphar.2015.12.001_bib38","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.neuropharm.2015.01.015","article-title":"The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2)","volume":"93","author":"Romermann","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2015.12.001_bib39","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.1074\/jbc.M109081200","article-title":"Transcellular transport of organic anions across a double-transfected Madin\u2013Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2\/SLC21A6) and Multidrug resistance-associated protein 2 (MRP2\/ABCC2)","volume":"277","author":"Sasaki","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2015.12.001_bib40","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1365-2710.1991.tb00337.x","article-title":"Factors influencing the protein binding of bumetanide using an equilibrium dialysis technique","volume":"16","author":"Shim","year":"1991","journal-title":"J. Clin. Pharm. Ther."},{"issue":"21","key":"10.1016\/j.ejphar.2015.12.001_bib41","doi-asserted-by":"crossref","first-page":"17308","DOI":"10.1074\/jbc.M112.356014","article-title":"Loop diuretic and ion-binding residues revealed by scanning mutagenesis of transmembrane helix 3 (TM3) of Na-K-Cl cotransporter (NKCC1)","volume":"287","author":"Somasekharan","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2015.12.001_bib42","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1124\/jpet.105.088104","article-title":"A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters","volume":"315","author":"Tahara","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2015.12.001_bib43","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/jcbfm.2014.4","article-title":"Hypoxia\/reoxygenation stress signals an increase in organic anion transporting polypeptide 1a4 (Oatp1a4) at the blood\u2013brain barrier: relevance to CNS drug delivery","volume":"34","author":"Thompson","year":"2014","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.ejphar.2015.12.001_bib44","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejphar.2014.11.019","article-title":"The organic anion transport inhibitor probenecid increases brain concentrations of the NKCC1 inhibitor bumetanide","volume":"746","author":"Tollner","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2015.12.001_bib45","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/j.1552-4604.1982.tb02648.x","article-title":"Protein binding and bilirubin displacing properties of bumetanide and furosemide","volume":"22","author":"Turmen","year":"1982","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2015.12.001_bib46","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1471-4159.2011.07208.x","article-title":"Quantitative targeted absolute proteomics of human blood\u2013brain barrier transporters and receptors","volume":"117","author":"Uchida","year":"2011","journal-title":"J. Neurochem."},{"issue":"12","key":"10.1016\/j.ejphar.2015.12.001_bib47","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1007\/s11095-007-9453-7","article-title":"Multichannel liquid chromatography\u2013tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter","volume":"24","author":"Uchida","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejphar.2015.12.001_bib48","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000480977","article-title":"Protein binding characteristics of bumetanide","volume":"12","author":"Walker","year":"1989","journal-title":"Dev. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2015.12.001_bib49","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ijpharm.2004.10.007","article-title":"Evaluation of the MDR-MDCK cell line as a permeability screen for the blood\u2013brain barrier","volume":"288","author":"Wang","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejphar.2015.12.001_bib50","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.neuroscience.2014.11.031","article-title":"In vivo effects of bumetanide at brain concentrations incompatible with NKCC1 inhibition on newborn DGC structure and spontaneous EEG seizures following hypoxia-induced neonatal seizures","volume":"286","author":"Wang","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejphar.2015.12.001_bib51","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0378-4347(91)80222-X","article-title":"Measurement of bumetanide in plasma and urine by high-performance liquid chromatography and application to bumetanide disposition","volume":"570","author":"Wells","year":"1991","journal-title":"J. Chromatogr."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299915303988?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299915303988?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T19:22:26Z","timestamp":1748719346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299915303988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":51,"alternative-id":["S0014299915303988"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2015.12.001","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro bidirectional permeability studies identify pharmacokinetic limitations of NKCC1 inhibitor bumetanide","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2015.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}